Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection
Primary Purpose
Traumatic Brain Injury
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
saline
Ketamine
Sponsored by
About this trial
This is an interventional treatment trial for Traumatic Brain Injury focused on measuring traumatic brain injury
Eligibility Criteria
Inclusion Criteria:
- are 1 month to 16 years of age; AND
- are admitted to the PICU following severe TBI (any GCS 3-8 inclusive) within 8 hours after the injury; AND
- are intubated and ventilated for the management of TBI; AND
- are anticipated to have an indwelling arterial or venous catheter for blood sampling during the first three days of study enrollment; AND
- have an intra-cranial pressure (ICP) monitoring device for management of TBI.
Exclusion Criteria:
- are less than 4 kilograms in weight upon admission
- are less than 1 month of age;
- are greater than 16 years of age;
- have a clinical diagnosis of non-accidental TBI;
- have suffered immersion injury or prolonged hypoxic injury (lasting greater than 10 minutes);
- have a known allergy to ketamine;
- have a planned removal of endotracheal tube or the removal of central venous catheter AND arterial catheter within 72 hours of study enrollment;
- have a current history of neuromuscular disease;
- have a current history of hepatic failure;
- have a current history of glaucoma
- require chronic treatment with anti-epileptic drugs (AEDs) or devices;
- more than 8 hours have elapsed from the time of injury to PICU admission;
- have documentation of a positive pregnancy test at the time of enrollment;
- if there is a lack of commitment to aggressive intensive care therapies (the subject is either on a DNR status due to pre-existing medical condition, or the family decides to withdraw support prior to participation in the study due to other multiple severe injuries and organ failures resulting from the trauma).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
1
2
Arm Description
Placebo Group receiving Saline Infusion.
Case Group receiving Ketamine infusion.
Outcomes
Primary Outcome Measures
To compare clinical, radiological, and neurodevelopmental outcomes between children who receive ketamine vs placebo infusions following traumatic brain injury.
Secondary Outcome Measures
To compare the expression of biomarkers of CNS injury between cases and controls.
Full Information
NCT ID
NCT00556387
First Posted
November 9, 2007
Last Updated
October 31, 2013
Sponsor
University of Arkansas
1. Study Identification
Unique Protocol Identification Number
NCT00556387
Brief Title
Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection
Official Title
Possible Neuroprotective Effects of Ketamine in Children With Severe Traumatic Brain Injury
Study Type
Interventional
2. Study Status
Record Verification Date
October 2013
Overall Recruitment Status
Withdrawn
Why Stopped
This study has been withdraw from the IRB. The PI has transferred to another university. The IND was transferred.
Study Start Date
December 2008 (undefined)
Primary Completion Date
December 2012 (Anticipated)
Study Completion Date
December 2012 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
University of Arkansas
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the possible effects of an anesthetic agent called Ketamine on the injured brain in children.
The researchers think that it will effect the outcomes of children with these injuries.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury
Keywords
traumatic brain injury
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Placebo Group receiving Saline Infusion.
Arm Title
2
Arm Type
Experimental
Arm Description
Case Group receiving Ketamine infusion.
Intervention Type
Drug
Intervention Name(s)
saline
Intervention Description
1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
Primary Outcome Measure Information:
Title
To compare clinical, radiological, and neurodevelopmental outcomes between children who receive ketamine vs placebo infusions following traumatic brain injury.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
To compare the expression of biomarkers of CNS injury between cases and controls.
Time Frame
96 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
are 1 month to 16 years of age; AND
are admitted to the PICU following severe TBI (any GCS 3-8 inclusive) within 8 hours after the injury; AND
are intubated and ventilated for the management of TBI; AND
are anticipated to have an indwelling arterial or venous catheter for blood sampling during the first three days of study enrollment; AND
have an intra-cranial pressure (ICP) monitoring device for management of TBI.
Exclusion Criteria:
are less than 4 kilograms in weight upon admission
are less than 1 month of age;
are greater than 16 years of age;
have a clinical diagnosis of non-accidental TBI;
have suffered immersion injury or prolonged hypoxic injury (lasting greater than 10 minutes);
have a known allergy to ketamine;
have a planned removal of endotracheal tube or the removal of central venous catheter AND arterial catheter within 72 hours of study enrollment;
have a current history of neuromuscular disease;
have a current history of hepatic failure;
have a current history of glaucoma
require chronic treatment with anti-epileptic drugs (AEDs) or devices;
more than 8 hours have elapsed from the time of injury to PICU admission;
have documentation of a positive pregnancy test at the time of enrollment;
if there is a lack of commitment to aggressive intensive care therapies (the subject is either on a DNR status due to pre-existing medical condition, or the family decides to withdraw support prior to participation in the study due to other multiple severe injuries and organ failures resulting from the trauma).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muayyad Tailounie, MD
Organizational Affiliation
Arkansas Children's Hospital Research Institute
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection
We'll reach out to this number within 24 hrs